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Fetal microchimerism in kidney biopsies of lupus
nephritis patients may be associated with a
beneficial effect
Greiciane MS Florim1, Heloisa C Caldas1, Julio CR de Melo1, Maria Alice SF Baptista1,2, Ida MM Fernandes1,2,
Marcela Savoldi-Barbosa3, Gustavo H Goldman3 and Mario Abbud-Filho1,2,4*
Abstract
Introduction: Microchimeric male fetal cells (MFCs) have been associated with systemic lupus erythematosus, and
published studies have further correlated MFC with lupus nephritis (LN). In the present study, we evaluated the
frequency of MFC in the renal tissue of patients with LN.
Methods: Twenty-seven renal biopsies were evaluated: Fourteen were from women with clinical and laboratory
findings of LN, and thirteen were from controls. Genomic DNA was extracted from kidney biopsies, and the male
fetal DNA was quantified using real-time quantitative polymerase chain reactions for the detection of specific Y
chromosome sequences.
Results: MFCs were detected in 9 (64%) of 14 of patients with LN, whereas no MFCs were found in the control
group (P = 0.0006). No differences in pregnancy history were found between patients with LN and the control
group. Significantly higher amounts of MFCs were found in patients with LN with serum creatinine ≤1.5 mg/dl.
Furthermore, women with MFCs had significantly better renal function at the time of biopsy (P = 0.03). In contrast,
patients with LN without MFCs presented with more severe forms of glomerulonephritis (World Health
Organization class IV = 60% and class V = 40%).
Conclusions: Our data indicate a high prevalence of MFCs in renal biopsy specimens from women with LN,
suggesting a role for MFCs in the etiology of LN. The present report also provides some evidence that MFCs could
have a beneficial effect in this disease.
Introduction
Renal involvement occurs in 50% to 70% of patients
with systemic lupus erythematosus (SLE) and is a major
cause of morbidity and mortality observed in this
disease. Lupus nephritis (LN) has a direct impact on
disease outcomes by causing damage to target organs,
with 10% to 30% of SLE patients developing end-stage
renal disease [1,2].
Several mechanisms have been reported to cause the
loss of self-tolerance present in SLE and contribute to
tissue injury and organ dysfunction, including heritable,
epigenetic, environmental, hormonal and immune regu-
latory factors [3].
As SLE affects women at a tenfold greater incidence
than men, and because these women present their first
symptoms most often during their fertile years, authors of
recent reports have postulated a role for microchimerism
among the etiologic factors of SLE [4]. Pregnancy is the
most important source of microchimeric cells, and the
circulation of these cells between mother and fetus also
causes maternal microchimerism. Therefore, it seems rea-
sonable to speculate that microchimeric cells, especially
those generated from male fetuses, could play a role in the
development of SLE and LN [5].
There are several reports in which microchimeric male
fetal cells (MFCs) have been described as being associ-
ated with immune-mediated diseases [6-9]. Although
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some authors have reported chimerism occurring twice
as often in kidneys of patients with LN, few authors have
correlated MFCs with LN, and these studies have often
yielded inconsistent results [10-13].
We have previously reported that patients with SLE
have more MFCs in the peripheral blood than healthy
women [14]. In the present study, we evaluated the
frequency of MFCs in the renal tissue of patients with
LN and whether MFCs could be associated with preg-
nancy history and the type of kidney injury observed
in biopsies.
Methods
Patients
Renal biopsies of 27 women were evaluated in this study:
14 from women with a diagnosis of LN (LN group) and 13
from women whose biopsies were performed for diagnosis
of other types of glomerulopathies (control group) without
a previous clinical history of autoimmune disease.
The inclusion criteria for both groups were having given
birth to at least one male child, having received no blood
transfusions and having had no previous organ transplants
or abortions. No patient in the LN group had been under-
gone dialysis at the time of biopsy.
By using a personal interview and questionnaire, a
detailed pregnancy history was taken from patients and
control subjects to collect demographic data, especially the
age at birth of first male child, the number of male preg-
nancies and the time since the birth of the first male child.
To ensure that inclusion criteria were strictly followed,
women without these data were not included in the study.
The study was approved by the institutional ethics
committee of the Medical School of Sao Jose do Rio
Preto (FAMERP) (number 5863/2011) in accordance with
current standards for human research, and informed
consent of all patients was obtained.
Diagnostic criteria
Patients with SLE were diagnosed according to the 1982
revised criteria of the American College of Rheumatology
for the diagnosis of SLE [15]. Histological findings of LN
from biopsies were classified according to the World
Health Organization (WHO) classification scheme, as up-
dated in 2003 by the International Society of Nephrology/
Renal Pathology Society [16]. Clinical diagnoses of LN
were made based on the finding of an “active” urinary
sediment (proteinuria >1+, erythrocytes >5,000/ml) and/
or serum creatinine ≥1.5 mg/dl and/or measured creatin-
ine clearance ≤60 ml/min/73 m2 and/or 24-hour protein-
uria >300 mg observed in at least two consecutive
outpatient appointments.
Activity and chronicity indices were estimated based
on the scoring system of Pollak et al. [17], as modified
by Austin et al. [18].
DNA extraction and real-time quantitative polymerase
chain reaction for detection of Y chromosome sequences
Genomic DNA was extracted from kidney biopsies
embedded in paraffin blocks using the RecoverAll™ Total
Nucleic Acid Isolation Kit for formalin fixation and par-
affin embedding (Ambion; Life Technologies, Carlsbad,
CA, USA), according to the manufacturer’s instructions.
Subsequently, the measurement of DNA concentration
by spectrophotometry was conducted (NanoDrop 2000
spectrophotometer; NanoDrop Products, Wilmington,
DE, USA) and the concentration of the genomic DNA
samples was adjusted to 50 ng/μl.
The amount of male fetal DNA present was determined
by real-time quantitative PCR (qPCR) through detection of
specific Y chromosome sequences using the StepOnePlus™
Real-Time PCR System, version 2.2 (Applied Biosystems;
Life Technologies).
The sex-determining region Y (SRY) TaqMan system
consisted of a forward primer: 5′-CGC ATT CAT CGT
GTG GTC TC-3′; a reverse primer: 5′-CTC TGA GTT
TCG CAT TCT GGG-3′; and a probe: (VIC; Life Tech-
nologies) 5′-CGA TCA GAG GCG CAA GAT GGC
TCT AG-3′ (tetramethylrhodamine) [19].
The SRY results were normalized using the threshold
cycle values obtained for β-actin (endogenous control)
amplified on the same plate [20].
The concentrations of male fetal DNA were expressed
as genome equivalents. One genome equivalent was
defined as the quantity of a particular DNA sequence
present in one diploid male cell [19]. All samples were
analyzed in duplicate.
Statistical analysis
Categorical variables were compared with the use of
the χ2 test. Continuous variables were compared with
Student’s t-test and the nonparametric were compared
with the Mann–Whitney U test. The Spearman correl-
ation test was used to identify trends between different
variables and the amount of MFCs. Multiple linear re-
gression analysis was used to evaluate possible depend-
ence of the amount of MFCs with continuous variables.
The Spearman correlation test was used to identify
trends between different variables and the amount of
MFCs. All data analyses were performed using GraphPad
Prism software (GraphPad Software, La Jolla, CA,
USA). P < 0.05 was considered significant.
Results
Pregnancy history of patients with lupus nephritis and
the control group
The LN and control groups showed no differences with
regard to age at time of biopsy, age at birth of first male
child, number of male pregnancies and time since birth
of the first male child.
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MFCs were detected in the renal biopsy specimens of
9 (64%) of 14 patients with a diagnosis of LN, whereas
no MFCs were found in the renal biopsy samples of the
control group (P = 0.0006, odds ratio = 46.6).
When we evaluated the amount of MFCs in the LN
group, we observed a trend toward a lower proportion
of MFCs in patients with a longer period of time since
the birth of the first male child (>15 years), when the
SLE diagnosis was made >5 years previously and among
multiparous women, although none of these factors
reached statistical significance. Interestingly, the propor-
tion of MFCs was almost 100-fold higher among women
presenting with better renal function at the time of
biopsy (serum creatinine levels ≤1.5 mg/dl = 9.5 ± 11.2
versus >1.5 mg/dl = 0.12 ± 0.2; P = 0.026) (Table 1).
Clinical and laboratory features of women with lupus
nephritis, with and without male fetal cells in renal tissue
As 5 (36%) of 14 patients with LN did not present with
MFCs in their renal tissue, we sought to determine pos-
sible differences between these two groups (Table 2). The
presence of MFCs in patients with LN was not associated
with any of the characteristics investigated (age at time of
biopsy, time since SLE diagnosis, age at birth of male
child, time since birth of first male child and number of
male pregnancies). However, it is worth noting that in the
group without MFCs, 40% of women were multiparous,
almost twofold higher compared with primiparous women
from the group with MFCs (22%) (Table 2). With regard
to renal function, both groups presented with similar 24-
hour proteinuria; however, women with MFCs had signi-
ficantly lower levels of serum creatinine at the time of
biopsy (with MFCs = 1.28 ± 0.73 mg/dl versus without
MFCs = 3.35 ± 2.9 mg/dl; P = 0.03) (Table 2).
Male fetal cells and the histological classification of lupus
nephritis
We also investigated whether MFCs were associated
with any specific histological features of LN. We found
that the most common forms of glomerulonephritis
among the study groups were diffuse proliferative glom-
erulonephritis (43%), followed by membranous glomer-
ulonephritis (29%), focal proliferative glomerulonephritis
(21%) and mesangial glomerulonephritis (7%). No biop-
sies were classified as class I or VI (Table 2). It must be
noted that patients with LN without MFCs predomin-
antly presented as glomerulonephritis class IV (60%) and
class V (40%) (Table 2).
When associations between the amount of MFCs and
histological LN class were investigated, we found a higher
proportion of MFCs in LN class III than in classes IV and V
(class III = 21.6 ± 6, class IV = 1.27 ± 2.9 and class V = 5.7 ±
11; P = 0.004) (Figure 1). Indices of activity and chronicity
of LN were not correlated with the amount of MFCs.
Discussion
Although fetal microchimerism is a common phenomenon
in biology and is found in healthy women many years after
pregnancy completion, only a few studies of its role in SLE
have been conducted [21]. Most researchers have investi-
gated the association of SLE and male microchimerism in
whole blood, and most of the reports have confirmed the
higher prevalence of MFCs in women with SLE than in
controls [11,14,22,23]. However, studies showing the
prevalence of MFCs in kidneys of patients with SLE and
LN are much scarcer [12,13,24,25].
Our study shows a significantly higher prevalence
(64%) of MFCs in kidney biopsies from women with SLE
and LN than in the control group, in which no MFCs
were found. No differences in pregnancy history were
found between the LN and control groups. Neither
could we find any correlation between pregnancy history
and the amount of MFCs detected. However, there was a
significantly higher amount of MFCs found in the group
of patients with LN presenting with serum creatinine
levels ≤1.5 mg/dl (Table 1).
Taken together, these data corroborate our previous
study in which we detected increased MFCs in whole
blood from patients with SLE and strongly suggest a role
for these MFCs in the etiopathogenesis of LN. Further-
more, our results are in line with other studies in which
authors reported an association between MFCs and LN
[12-14,24,25]. In two different studies, Kremer-Hovinga
et al. investigated the presence of the Y chromosome
using fluorescence in situ hybridization (FISH). Micro-
chimeric cells were found in 55% of renal biopsy samples
Table 1 Amount of male fetal cells in renal biopsies from
patients with lupus nephritis, pregnancy history and
serum creatinine levelsa
Characteristic LN group (n = 14) P-value
Time since birth of first male child (yr)
1 to 15 (n = 5) 9.25 ± 12.37 NS
>15 (n = 9) 5.5 ± 9.6
Time since SLE diagnosis (yr)
1 to 5 (n = 5) 10 ± 13.6
NS
>5 (n = 9) 5.08 ± 8
Number of male pregnancies
1 (n = 0) 7.99 ± 10.75 NS
>1 (n = 4) 3.7 ± 7.5
Serum creatinine (mg/dl)
≤1.5 mg/dl (n = 10) 9.5 ± 11.2
0.026
>1.5 mg/dl (n = 3) 0.12 ± 0.2
aLN, Lupus nephritis; NS, Not significant; SLE, Systemic lupus erythematosus.
Data are given as mean ± standard deviation.
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from women with LN and in 25% of kidney autopsy
specimens without histomorphologic lesions that served
as controls [12]. In the second study, microchimerism
was investigated in postmortem tissues from seven
patients with SLE, and the researchers then compared
these tissues with histologically normal organs from 34
control women. Chimeric MFCs were found in all seven
patients and in 44% of the controls [24].
Khosrotehrani et al. could not find an association
between microchimeric MFCs and SLE using the FISH
method to detect the Y chromosome in skin tissue from
women with SLE [26]. However, in a case report study of
a woman with severe SLE, the same group of authors
demonstrated the presence of a large number of MFCs in
necropsy specimens from clinically affected tissues [25].
Although our results are generally in agreement with
these previous studies, we did not find any microchi-
meric MFCs in our control group. This divergence may
be the result of different techniques used to detect
microchimerism and especially of the fact that strict
Table 2 Pregnancy history, renal function and histological classification of renal biopsies of patients with lupus
nephritis divided into groups containing renal biopsies either with or without male fetal cellsa
Characteristics With MFCs Without MFCs P-value
Number (%) 9 (64) 5 (36)
Age at biopsy (yr), median (range) 38 (22 to 48) 41 (32 to 56) NS
Time since SLE diagnosis (yr) 6.1 ± 7.6 9.4 ± 4 NS
Age at birth of the first male child (yr) 21.5 ± 3.9 22.6 ± 3.8 NS
Time since birth of the first male child (yr) 16.3 ± 7.7 21 ± 7.3 NS
Number of male pregnancies, n (%)
1 7 (77.8) 3 (60) NS
>1 2 (22.2) 2 (40) NS
Serum creatinine (mg/dl) 1.28 ± 0.73 3.35 ± 2.9 0.03
Proteinuria (g/24 hr) 1.78 ± 1.2 1.15 ± 0.7 NS
Histological classification of renal biopsiesb, n (%)
Mesangial glomerulonephritis (class II) 1 (11.1) 0 (0) NS
Focal proliferative glomerulonephritis (class III) 3 (33.3) 0 (0) NS
Diffuse proliferative glomerulonephritis (class IV) 3 (33.3) 3 (60) NS
Membranous glomerulonephritis (class V) 2 (22.2) 2 (40) NS
aLN, Lupus nephritis; MFC, Male fetal cell; NS, Not significant. Data are given as mean ± standard deviation. bWorld Health Organization classification scheme, as
updated in 2003 by the International Society of Nephrology/Renal Pathology Society [16]. No class I or VI biopsies were found.
Figure 1 Amount of male fetal cells in renal biopsies and the associated histological lupus nephritis class. MFC, Male fetal cells. *P < 0.01 for class
III versus class IV; **P < 0.05 for class III versus class V.
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exclusion criteria for pregnancy history and blood trans-
fusion were not employed in the other studies.
Furthermore, comparisons of results between different
studies should be interpreted with caution for several
reasons. (1) Few reports are available, and only a small
number of patients have been studied. (2) Different
methods have been used to detect MFCs in different tis-
sues. (3) There is a lack of strict inclusion and exclusion
criteria to assess history of blood transfusion and preg-
nancy/abortion. (4) Control groups studied have in-
cluded biopsies that varied from biopsies taken from
patients with other kidney diseases to tissue specimens
obtained postmortem. (5) The effect of SLE treatments
on microchimeric cells is unknown.
Our results also suggest that LN can occur in the ab-
sence of microchimerism, because 36% of women in the
SLE with LN group did not present MFCs in renal tissue
(Table 2). Using different techniques, other researchers
have reported similar prevalences (between 45% and
54%), and although MFCs can remain in the peripheral
blood for years, it is unknown how long these cells could
remain in the tissues [12,13,24].
Again, analysis of pregnancy history of patients with
LN with versus without MFCs did not show significant
differences between the two groups (Table 2). However,
as observed earlier in the overall analysis of the women
with LN, the group in which microchimerism was
present had significantly lower levels of serum creatinine
than the group without MFCs (Table 2).
The role of fetal microchimerism in SLE is controversial,
raising the question whether these cells are targets or
innocent bystanders [27]. One hypothesis is that micro-
chimeric cells could provide a chronic source of foreign
antigens, generating persistent inflammation and leading
to injury and release of additional foreign antigens. As for-
eign antigens, these microchimeric cells could be involved
in interactions between host and nonhost cells, similar to
graft-versus-host disease after stem cell transplantation,
and trigger autoimmune disease [28].
Another possibility is the repair hypothesis, wherein the
microchimeric cells are involved in repair mechanisms
and, in response to inflammation and chronic tissue dam-
age, these cells are actively recruited to the injured tissue
and help in the repair and regeneration process [28].
Also, the low levels of MFCs could be an advantage
because they could be tolerated by the immune system
and could be recruited to the damage tissue and aid in
the repair process [27]. Additionally, microchimeric cells
have been identified as being mesenchymal stem cells
based on their morphology and immunophenotype. As a
consequence, their capacity for transdifferentiation in
tissue repair could alter the tissue microenvironment by
secretion of soluble factors and amelioration of tissue
damage in response to injury and disease [29,30].
Although renal biopsy plays a crucial role in the diag-
nosis of the specific form of LN, its role in predicting
disease outcome has been controversial [18]. Therefore,
we sought to find an association between the type of
glomerular lesion in LN and MFCs. Contrary to Kremer-
Hovinga et al., we found a similar distribution of WHO
glomerulonephritis classes among patients with LN,
although a trend toward a higher prevalence of class IV
was observed (Table 2) [12]. Similar results were seen
among patients in whom MFCs were present. In con-
trast, all five patients with LN without MFCs had only
either class IV or class V glomerulonephritis. If we arbi-
trarily consider classes IV and V as the most severe stages
of glomerular disease, these findings suggest a possible as-
sociation between the severity of LN and the absence of
MFCs, highlighting that the development of microchimer-
ism could have a beneficial effect in LN [31].
Additionally, it was reported previously that elevated
serum creatinine at the time of the kidney biopsy is associ-
ated with an increased risk of chronic renal failure [32].
As we found lower serum creatinine levels to be asso-
ciated with a higher amount of MFCs and, contrarily,
worse renal function in the group without MFCs, ours
results are in line with the hypothesis that the presence
of MFCs at the time of renal biopsy could have a pro-
tective role in LN. These findings also lend support to
the possibility that these cells are tolerated by the im-
mune system and that, in response to tissue injury, they
would be recruited to the injured site and aid in the
repair [27].
We do acknowledge that limitations of the present in-
vestigation are the small sample size studied and the inclu-
sion and exclusion criteria used, which could introduce
some bias when interpreting results. Probably, these limi-
tations justify the scarce number of reports in this subject
area in the existing literature. However, as far as we know,
this is the first study in which a very sensitive molecular
technique, real-time qPCR, was used to quantify MFCs in
renal biopsy samples. Furthermore, to avoid false-positive
chimerism due to undetected miscarriage and blood trans-
fusions, we used a very strict questionnaire to interview all
women included in the study, resulting in the detection of
MFCs being consistently negative in our control group.
Conclusions
Our data indicate a high prevalence of MFCs in renal bi-
opsy specimens from women with LN, suggesting a role
for these microchimeric cells in the etiology of LN. The
present report also provides some evidence that MFCs
could have a beneficial effect on the disease process.
Nonetheless, the true biologic significance of MFCs and
whether they act as protectors or insurgents in SLE and
LN remain to be elucidated, and thus further multicen-
ter studies are required.
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